![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Debiopharm International S.a. Lausanne Ch, based in Switzerland, is a pharmaceutical company.
One of their significant offerings is Oxaliplatin, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2003-018 - Rev 02
This Chemical Type CEP, issued on July 23, 2013, remains in force until March 27, 2018, ensuring its reliability within the pharmaceutical industry.
Substance Number 2017 associated with this CEP further emphasizes